When the fat underneath disappears through weight loss, the skin is left with more surface area than it needs
Advances in Therapy , 37(3), 1087-1099
Several factors influence tirzepatide's pharmacokinetics: Elimination pathway : Tirzepatide is primarily eliminated through proteolytic breakdown in the body, not through renal excretion Dose and duration of treatment : Higher doses and longer treatment periods result in greater drug accumulation Body weight : Body weight is a known covariate that can modestly affect drug exposure Steady-state concentrations : With weekly dosing, tirzepatide reaches steady-state levels after approximately 4 weeks of consistent administration According to FDA prescribing information, no dose adjustment is required for patients with renal impairment (including end-stage renal disease) or hepatic impairment, as these conditions do not significantly affect tirzepatide clearance
Malabsorption disorders : Patients with conditions like Crohns disease, celiac disease, or pernicious anemia that affect the absorption of nutrients may require more frequent injections, approximately every 4-8 weeks
Talk to your veterinarian about any side effect that seems unusual or bothersome to your pet
Tirzepatide : Used for significant weight loss and lowering blood sugar
